|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, DeSantis C, Virgo K, et al:
Cancer treatment and survivorship statistics, 2012. CA Cancer J
Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
American Cancer Society. Prostate cancer
facts and statistics. http://www.cancer.org/cancer/prostatecancer/index.
November 13–2013
|
|
4
|
Cook LS, Goldoft M, Schwartz SM and Weiss
NS: Incidence of adenocarcinoma of the prostate in Asian immigrants
to the United States and their descendants. J Urol. 161:152–155.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Arya M, Bott SR, Shergill IS, Ahmed HU,
Williamson M and Patel HR: The metastatic cascade in prostate
cancer. Surg Oncol. 15:117–128. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Adlercreutz H: Western diet and Western
diseases: some hormonal and biochemical mechanisms and
associations. Scand J Clini Lab Invest Suppl. 50:3–23. 1990.
View Article : Google Scholar
|
|
7
|
Birt DF, Mitchell D, Gold B, Pour P and
Pinch HC: Inhibition of ultraviolet light induced skin
carcinogenesis in SKH-1 mice by apigenin, a plant flavonoid.
Anticancer Res. 17:85–91. 1997.PubMed/NCBI
|
|
8
|
Yang CS, Landau JM, Huang MT and Newmark
HL: Inhibition of carcinogenesis by dietary polyphenolic compounds.
Annu Rev Nutr. 21:381–406. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Patel D, Shukla S and Gupta S: Apigenin
and cancer chemoprevention: Progress, potential and promise
(review). Int J Oncology. 30:233–245. 2007.
|
|
10
|
Shukla S and Gupta S: Molecular targets
for apigenin-induced cell cycle arrest and apoptosis in prostate
cancer cell xenograft. Mol Cancer Ther. 5:843–852. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Van Dross RT, Hong X and Pelling JC:
Inhibition of TPA-induced cyclooxygenase-2 (COX-2) expression by
apigenin through downregulation of Akt signal transduction in human
keratinocytes. Mol Carcinog. 44:83–91. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gupta S, Afaq F and Mukhtar H: Selective
growth-inhibitory, cell-cycle deregulatory and apoptotic response
of apigenin in normal versus human prostate carcinoma cells.
Biochem Biophys Res Commun. 287:914–920. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yilmaz M and Christofori G: EMT, the
cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev.
28:15–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Caltagirone S, Rossi C, Poggi A, et al:
Flavonoids apigenin and quercetin inhibit melanoma growth and
metastatic potential. Int J Cancer. 87:595–600. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang IK, Lin-Shiau SY and Lin JK:
Induction of apoptosis by apigenin and related flavonoids through
cytochrome c release and activation of caspase-9 and caspase-3 in
leukaemia HL-60 cells. Eur J Cancer. 35:1517–1525. 1999. View Article : Google Scholar
|
|
16
|
Wang W, Heideman L, Chung CS, Pelling JC,
Koehler KJ and Birt DF: Cell-cycle arrest at G2/M and growth
inhibition by apigenin in human colon carcinoma cell lines. Mol
Carcinog. 28:102–110. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yin F, Giuliano AE, Law RE and Van Herle
AJ: Apigenin inhibits growth and induces G2/M arrest by modulating
cyclin-CDK regulators and ERK MAP kinase activation in breast
carcinoma cells. Anticancer Res. 21:413–420. 2001.PubMed/NCBI
|
|
18
|
Albini A, Iwamoto Y, Kleinman HK, et al: A
rapid in vitro assay for quantitating the invasive potential of
tumor cells. Cancer Res. 47:3239–3245. 1987.PubMed/NCBI
|
|
19
|
Jaggi M, Johansson SL, Baker JJ, Smith LM,
Galich A and Balaji KC: Aberrant expression of E-cadherin and
beta-catenin in human prostate cancer. Urol Oncol. 23:402–406.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial-mesenchymal transition during tumor
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sarkar FH, Li Y, Wang Z and Kong D:
Pancreatic cancer stem cells and EMT in drug resistance and
metastasis. Minerva Chir. 64:489–500. 2009.PubMed/NCBI
|
|
23
|
Vleminckx K, Vakaet L Jr, Mareel M, Fiers
W and van Roy F: Genetic manipulation of E-cadherin expression by
epithelial tumor cells reveals an invasion suppressor role. Cell.
66:107–119. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bates RC and Mercurio AM: The
epithelial-mesenchymal transition (EMT) and colorectal cancer
progression. Cancer Biol Ther. 4:365–370. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thiery JP: Epithelial-mesenchymal
transitions in development and pathologies. Curr Opin Cell Biol.
15:740–746. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Branton MH and Kopp JB: TGF-beta and
fibrosis. Microbes Infect. 1:1349–1365. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chaffer CL, Brennan JP, Slavin JL, Blick
T, Thompson EW and Williams ED: Mesenchymal-to-epithelial
transition facilitates bladder cancer metastasis: role of
fibroblast growth factor receptor-2. Cancer Res. 66:11271–11278.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhu Y, Mao Y, Chen H, et al: Apigenin
promotes apoptosis, inhibits invasion and induces cell cycle arrest
of T24 human bladder cancer cells. Cancer Cell Int. 13:542013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lepley DM, Li B, Birt DF and Pelling JC:
The chemopreventive flavonoid apigenin induces G2/M arrest in
keratinocytes. Carcinogenesis. 17:2367–2375. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lepley DM and Pelling JC: Induction of
p21/WAF1 and G1 cell-cycle arrest by the chemopreventive agent
apigenin. Mol Carcinog. 19:74–82. 1997. View Article : Google Scholar : PubMed/NCBI
|
